FATE
Fate Therapeutics, Inc. · Healthcare
Redmile Group, LLC bought $1.7M of Fate Therapeutics, Inc.
Director and 10% owner
Bought$1,705,829
$6.17Price
276,639Shares
+2%Stake
What FATE did for a copier
- $1,000 copied at Mon, Apr 24 open, $6.36
- $868
- S&P 500, same days
- +3.9%
Measured over 30 trading days, to the Jun 6 close.
Redmile Group, LLC's record
10 other buys with 3 months of prices since 2016: on average −13.6% against the S&P 500, and 3 of 10 beat it.
We're building an app that can copy buys like this into your own brokerage. Join the waitlist
Traded Thu, Apr 20. Filed Fri, Apr 21. Returns use the Apr 24 open and the Jun 6 close. Not investment advice.